CompletedPhase 2NCT03144687
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Peter Langmuir, MDIncyte Corporation
- Intervention
- Itacitinib(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2021
Study locations (26)
- Arizona Oncology Associates, Tempe, Arizona, United States
- UC Irvine Medical Center, Orange, California, United States
- Anschutz Cancer Pavilion - University Of Colorado, Aurora, Colorado, United States
- Rocky Mountain Cancer Center, Colorado Springs, Colorado, United States
- Rocky Mountain Cancer Center, Denver, Colorado, United States
- Norwalk Hospital, Norwalk, Connecticut, United States
- Parkview Research Center, Fort Wayne, Indiana, United States
- University of Michigan Cancer Center, Ann Arbor, Michigan, United States
- Providence Cancer Center, Southfield, Michigan, United States
- Nebraska Cancer Specialist, Omaha, Nebraska, United States
- University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Willamette Valley Cancer Institute, Eugene, Oregon, United States
- Consultants in Medical Oncology and Hematology, PC, Broomall, Pennsylvania, United States
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03144687 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGNANCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)University Hospital, Bordeaux
- RECRUITINGPHASE2NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNCT07165535Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology NetworkUniversity of Milano Bicocca
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami